Brian Bertha VP, Corporate Strategy and Business Development McKesson U.S. Pharmaceutical

Similar documents
McKesson Corporation J.P. Morgan Healthcare Conference

2009 UBS Healthcare Services Conference

Innovative Strategies for Managing the Rising Cost of Specialty Drugs

Delivering Value for All Health Care Stakeholders. Larry Merlo President & Chief Executive Officer

Medicaid Program; Covered Outpatient Drugs; Proposed Rule (CMS-2345-P) NHIA Summary

Understanding Pharmacy Benefit Management Services

NCPA Summary of CMS Medicaid Covered Outpatient Drugs AMP Final Rule Prepared January NCPA Advocacy at Work

KEEPING PRESCRIPTION DRUGS AFFORDABLE: The Value of Pharmacy Benefit Managers (PBMs)

Medicaid Prescription Drug Payment Reform

Disease Management and the Medicare Drug Benefit: Opportunities and Threats for the Pharmaceutical Industry

McKesson Corporation J.P. Morgan Healthcare Conference

Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy

Jill Rosenthal, MD, MA, MPH, FACOEM SVP, Chief Medical Officer Zenith Insurance Company

Insightsfeature. Managing Specialty Drug Spend Under the Medical Benefit. Innovations and Automation for More Effective Management.

Pharmacy Benefit Managers Overview

THIRD-PARTY PHARMACY RECONCILIATION

UC SHIP Premium Formulary. Effective September 1, 2016

Walgreens Boots Alliance 2015 analyst meeting financial session. Safe Harbor and Non-GAAP

Investor Conference. Health Net Pharmaceutical Services

Pharmaceutical Market Trends

Pay for Performance & the Changing Landscape for Pharmacy: A Panel Discussion

Q Formulary Performance:

DIR: Trends, Issues, and Impending Impacts

Pharmacy Benefit Managers (PBMs)

I. PURPOSE. A. The primary objectives of Molina Healthcare s Transition Policy and Procedure are:

December 15, 2017 (31 State SPAs)

Third Quarter 2017 Earnings Conference Call

How Medication Adherence and Outcomes Are Changing the Business Model

How you are being measured by health plans, PBMs and accreditation organizations. December 2013

Standing strong for payers and patients

Medicare Congress: Fee for Service Trends: A Look at Medicare Part B

Impact of the AMP Final Rule on Class of Trade & Contracting

RISK SHARE AGREEMENTS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

Contents General Information General Information

FREQUENTLY ASKED QUESTIONS ABOUT THE CVS CAREMARK PRESCRIPTION DRUG PROGRAM

Growth in an Evolving Health Care Market

Amerigroup Medicare Member PBM Conversion Talking Points

Survey Analysis of January 2014 CMS Medicare Part D Proposed Rule

INDUSTRY TRENDS IN PHARMACY REIMBURSEMENT

Unique PBM Capabilities

Patient Assistance Resources

Second Quarter 2017 Earnings Conference Call

Puma Biotechnology 3Q Earnings Call Commercial Update

Drug Costs Driven By Rebates

Pharmacy Trend Management

Prescription Drug Plan Update

The Declining Value of Payer Access: Defining and improving Rebate Efficiency in the current healthcare landscape

Prescription Drugs Spending Distribution and Cost Drivers. Steve Kappel January 25, 2007

Savings Generated by New York s Medicaid Pharmacy Reform

Contracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress. October 20, 2016

Plan Comparison Checklist

A Unique Vision of Care. Jefferies 2014 Global Healthcare Conference June 3, 2014

Puma Biotechnology Earnings Call Commercial Update

Pharmacy Benefit Management in Oncology

Share a Clear View PHARMACY BENEFIT

SelectHealth Prescriptions

Marc Claussen, Chiesi USA, Director, Market Access. Donna White, Chiesi USA, Sr. Director, Contracting and Compliance

Understanding Your Prescription Program. CCIU Employee Meeting September 7, 2016

CVS HEALTH CORP FORM 10-K. (Annual Report) Filed 02/11/14 for the Period Ending 12/31/13

How the Blueprint Policy Statement to Lower Drug Costs and Reduce Out-of- Pocket Costs May Affect Employers

Standing strong for payers and patients

April 8, Dear Mr. Levinson,

2019 Transition Policy

Pharmaceutical Management Community Plans 2018

Pharmaceutical Management Commercial Plans

State Bill Status Category Summary 4/11/ Referred to House of Representatives Ways and Means Committee

The U.S. Healthcare System: How Pharmacy Benefit Managers Impact Prescription Drug Use. Presented by Daniel Tomaszewski Pharmd, PhD

DIR FEES: WHAT YOU NEED TO KNOW JULY 13, :00 10:00 AM

CDHP Special Administration

Walgreen Co. Reports Fiscal 2014 Second Quarter Results

Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes

The Real Deal About Real-Time Benefits. Proven Savings with Up-to-the-Minute, Member-Specific Information Across Multiple Points of Care

Prescription Drug Coverage

Sanford C. Bernstein Twenty-Second Annual Strategic Decisions Conference 2006

Fourth Quarter 2018 Earnings Conference Call

Moving From Offers to Solutions

Chapter 10 Prescriptions Benefits and Drug Formulary

Avalere Health 2015 Industry Outlook

DIR fees are knocking down pharmacy profits

SecurityBlue HMO. Link to Specific Guidance Regarding Exceptions and Appeals

HealthEZ doesn t serve clients; we serve people. We are here to take care of you. We are here to serve you!

Safe Harbor Statement

Testimony of Mark Merritt. Pharmaceutical Care Management Association

MEASURING THE IMPACT OF POINT OF SALE REBATES IN COLORADO S COMMERCIAL MARKET

BlueRx PDP. Link to Specific Guidance Regarding Exceptions and Appeals

1 sur 10 03/02/ :56

Overview of Coverage of Drugs Under the Medicaid Medical Benefit

SAVINGS GENERATED BY PHARMACY BENEFIT MANAGERS IN THE MEDICARE PART D PROGRAM

BERKELEY RESEARCH GROUP. Executive Summary

Diplomat Announces 4th Quarter and 2017 Year End Financial Results; Provides 2018 Guidance

WorldatWork You and Your PBM: Improving Discounts, Fees and Rebates, and Beyond. Kristin Begley, Pharm.D. Principal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

BENCHMARKING REPORT. Sponsored by PCCA

The Sunshine Act: Where it stands, where it s going and compliance implementation

TAKING ACTION AGAINST RISING GENERIC PRICES

Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President (401) (401) FOR IMMEDIATE RELEASE

COMPLIANCE WITH PATIENT ASSISTANCE PROGRAMS AND CO-PAY CARDS. Judd Katz JD MHA November 2016

Pharmacy Benefit Strategies for Lowering Prescription Drug Costs

HealthEZ doesn t serve clients; we serve people. We are here to take care of you. We are here to serve you!

Transcription:

Brian Bertha VP, Corporate Strategy and Business Development McKesson U.S. Pharmaceutical

2 Safe Harbor Clause Some of the information in this presentation may constitute forwardlooking statements that are subject to various uncertainties. These uncertainties could cause actual results to differ materially from those projected or implied. The risk factors associated with those uncertainties are described in the Company s reports and exhibits filed with the Securities and Exchange Commission. Financial information is presented here in summary form. Full details are provided in the Company s most recent 10-K report. All of this information is available at www.mckesson.com. The Company assumes no obligation to update or revise any such statements, whether as a result of new information or otherwise.

3 Long-term Relationships with Market Leaders Vanderbilt University Medical Center

4 Conference highlights Opening General Session Future of Pharmacy Plenary Session Generics Insight Theater Series Automation Health Mart Diabetes Shopper Insights Clinical Services Continuing Education Networking opportunities

5 A changing environment forces retail independents to evolve The biggest chains are getting bigger Mail order continues to grow, but many new entrants New type of competition emerges with CVS/CMX merger Demand for better pharmaceutical care is growing Chains look to stake out claim for clinical care

6 AMP ruling: to early to assess impact Excludes sales to Pharmacy Benefit Managers (PBMs) and pharmacies serving nursing homes and assisted living facilities; sales to mail order pharmacies remain included Excludes manufacturer coupons redeemed by an agent, pharmacy or entity acting on behalf of the manufacturer to the list of prices Excludes that manufacturer vouchers and manufacturer-sponsored drug discount card programs Excludes outlier AMPs, meaning that the lowest AMP in a FUL group will be excluded if it is less than 40 percent of the next highest AMP (this is a change from 30% in the proposed rule) Includes home infusion and specialty pharmacies Requires manufacturers to submit quarterly and monthly AMPs to CMS. Manufacturers must estimate the impact of lagged price concessions using a 12-month rolling average.

7 Generics wave provides benefits to retail independents and McKesson 05 09 Patent Expiry Branded Value $ Billions $16 $15 $14 $11 $10 McKesson is the largest distributor of generics New GenericsConnect telemarketing program enhances relationships with existing customers McKesson OneStop Generics is leading generics program in independent market Recently signed new single-source agreement with APCI 2005 2006 2007 2008 2009 Source: FDA; IMS Health; Bernstein Analysis

The future of independent pharmacy 8

Last year, Health Mart was in 29 states, focused in the Midwest and South 9

Today, we are coast-to-coast in 48 states 10

11 We are beginning to see strong statewide penetration in the independent market State Health Marts today Health Marts last year % of independents CA 112 6 6% FL 97 38 WI 82 12 TX 77 4 GA 59 19 12% 25% 6% 9% NE 57 14 29% IA 51 8 15% MORE.

Health Mart stores represent our best customers $2.8 $2.7 $2.7 $2.6 $2.6 $2.5 $2.5 $2.4 $2.4 $2.3 $2.3 $2.7M HM Avg. Store Sales $2.4M Non-HM 14.0% 12.0% 10.0% 8.0% 6.0% 4.0% 2.0% 0.0% 13.2% HM Same Store Growth 10.9% Non-HM 99.0% 98.0% 97.0% 96.0% 95.0% 94.0% 93.0% 92.0% 91.0% 90.0% 89.0% 98% Retention 92% 18.0% 16.0% 14.0% 12.0% 10.0% 8.0% 6.0% 4.0% 2.0% 0.0% 15.8% McK Gx: Rx 13% HM Non-HM HM Non-HM 12

Health Mart brings together key capabilities 13

14 McKesson embarked on intense study on the full potential of Health Mart Completed market research with all stakeholders Analyzed value proposition Benchmarked franchise best-practices worldwide Examined full potential of franchise 3-5 years out Analyzed store requirements and compliance guidelines Developed staged implementation plan

15 The future of Health Mart today 18 months 36 months Managed care PBM recognition Branding Consumer recognition In-Store Programs Manufacturer recognition Community Industry recognition Reimbursement optimization National advertising Leader in cognitive services Ownership expansion

16 Connectivity unleashes value National Payors Manufacturers Back-office Services MTM & Adherence Central Fill Prescription Transfers Auto Refills Loyalty Cards Pharmaceutical Care Physicians & Local Payors Long Term Care Direct to Patient

Q&A 17